Sharp Edge Labs Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $4.1M
Latest Deal Amount
  • Investors
  • 6

Sharp Edge Labs General Information

Description

Operator of a preclinical-stage life sciences intended to develop proprietary biological assays for protein trafficking disorders. The company's platform develops a new class of targeted biosensors for drug discovery and trafficking biology which provide an accurate and detailed detection method for cellular trafficking, enabling pharmaceutical and biotechnology companies to accelerate the development of new medicines.

Contact Information

Website
www.sharptx.com
Formerly Known As
Sharp Edge Technologies
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 2403 Sidney Street
  • Suite 264
  • Pittsburgh, PA 15203
  • United States
+1 (412) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sharp Edge Labs Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 21-Aug-2019 $4.1M 00.000 Completed Generating Revenue
7. Later Stage VC (Series C) 06-Jul-2017 00.000 00.000 00.000 Completed Generating Revenue
6. Later Stage VC (Series B) 20-Aug-2014 00000 00.000 00.000 Completed Generating Revenue
5. Later Stage VC (Series A1) 09-Jul-2013 00000 00000 000 Completed Generating Revenue
4. Grant 24-Sep-2012 00000 00000 Completed Generating Revenue
3. Later Stage VC 04-Jan-2012 00000 00000 Completed Generating Revenue
2. Later Stage VC (Series A) 30-Dec-2010 $300K $300K 000 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Sharp Edge Labs’s complete valuation and funding history, request access »

Sharp Edge Labs Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series A1 202,321 $0.000010 8% $1.25 $1.25 1x $1.25 4.73%
Series A 460,000 $0.000010 8% $1 $1 1x $1 10.75%
To view Sharp Edge Labs’s complete cap table history, request access »

Sharp Edge Labs Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a preclinical-stage life sciences intended to develop proprietary biological assays for protein trafficking
Biotechnology
Pittsburgh, PA
7 As of 2021
00.000
0000000000 0 00.000

00000 00

d tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercita
0000 000000000
South San Francisco, CA
00 As of 0000
00000
000000000 00000

00000000

incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ull
0000 000000000
London, United Kingdom
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sharp Edge Labs Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Senti Bio Venture Capital-Backed South San Francisco, CA 00 00000 000000000 00000
000000000000 Private Equity-Backed London, United Kingdom 000 00000 000000000 00000
000000000 00000000 Private Equity-Backed Nottingham, United Kingdom 000 00000000000
0000000 0000000000 Formerly VC-backed Brisbane, CA 000 0000 00000000 0000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 50 competitors. Get the full list »

Sharp Edge Labs Executive Team (4)

Name Title Board Seat Contact Info
Scott Sneddon Ph.D President, Chief Executive Officer & Board Member
Marcel Bruchez Ph.D Scientific Co-Founder, Board Member, Chief Technology Officer & Chief Scientific Officer
Chris Szent-Gyorgyi Ph.D Co-Inventor, Equity Holder and Consultant
Alan Waggoner Ph.D Scientific Co-Founder, Board Member & Chief Architect Officer
To view Sharp Edge Labs’s complete executive team members history, request access »

Sharp Edge Labs Board Members (5)

Name Representing Role Since
Alan Waggoner Ph.D Sharp Edge Labs Scientific Co-Founder, Board Member & Chief Architect Officer 000 0000
Marcel Bruchez Ph.D Sharp Edge Labs Scientific Co-Founder, Board Member, Chief Technology Officer & Chief Scientific Officer 000 0000
Stephan Dietrich Sharp Edge Labs Board Member 000 0000
William Newlin Ph.D Newlin Investment Company Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Sharp Edge Labs Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sharp Edge Labs Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Topanga Partners Venture Capital Minority 000 0000 000000 0
Pittsburgh Life Sciences Greenhouse Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Innovation Works Venture Capital Minority 000 0000 000000 0
Newlin Investment Company Growth/Expansion Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial